I hold these stock.

DYOH (do your own homework.)

To-day there was a slight drop in price, but number of analysts are giving favourable reports.

What triggered my interest was better than expected results and if I am right looking at charts it shows an inverted head and shoulders. Hopefully a good sign. Also the current rate of Share price growth is about 90% pa over the last 5weeks. This is unlikely to continue indefinitely but SP could hit 850p over next few weeks.

To-day at close, there were some large buys of about 5million shares. 40million approx.

Another trigger for me was the following which should increase earnings.

Aviva to form JV in Taiwan with First FinancialAFX
LONDON (Thomson Financial) - Aviva PLC, the UK's largest insurer, said it has entered into a joint venture with First Financial Holding Co Ltd to sell insurance and pension products in Taiwan. The joint venture company, First-Aviva, will distribute long-term savings and pension products in Taiwan through an exclusive agreement with First Financial's flagship unit, First Commercial Bank. Aviva, which will have a 49 pct stake in the joint venture, added that the initial paid up capital of the new company will be 34 mln stg.First Commercial Bank is Taiwan's second largest bank network, with five mln retail customers, it added.TFN.newsdesk@thomson.comkkb/faj/slm




Date: Wednesday 25 Apr 2007
LONDON (ShareCast) - If the message gets home that Aviva will not bid for Prudential, the stock should rebound strongly, especially if Aviva can sustain its current impressive performance. There is still work to be done but, at 794.5p, the shares are a strong buy says the Independent.
Date: Tuesday 24 Apr 2007
LONDON (ShareCast) - Aviva stood out among the risers on a tough day for blue chip stocks. The life insurer posted an upbeat first quarter statement with brokers pleased with the numbers.



DYOH

Iowa insurance commissioner approves Athene's $1.55 billion buyout of Aviva USA

NEW YORK | Thu Aug 15, 2013 8:22pm BST
(Reuters) - The Iowa insurance commissioner approved Athene Holding Ltd's pending $1.55 billion (990.47 million pounds) purchase of British insurer Aviva Plc's (AV.L) U.S. annuity business, the state said on Thursday.

Aviva's U.S. operations are headquartered in Iowa, and approval from that state and New York were two regulatory hurdles for the deal, Apollo said in an August 8 earnings call.

Bank of America Merrill Lynch Buy 404.30 404.30 475.00 475.00 Retains

Morgan Stanley Overweight 391.00 391.00 403.00 445.00 Reiterates

Bank of America Merrill Lynch Buy 411.40 475.00 475.00 Retains

Doing nicely!

F&C Asset Management Increase Holding http://www.moneyam.com/action/news/showArticle?id=4669580

Goldman Sachs Neutral 415.10 415.10 405.00 430.00 Retains

Aviva Completes Sale of Aviva USA

Aviva plc ("Aviva") announces that it has completed the sale of Aviva USA Corporation, its US life and annuities business ("Aviva USA"), to Athene Holding Ltd ("Athene").

The transaction proceeds are US$2.6bn[1] (£1.7bn) and are subject to customary completion adjustments. The proceeds are US$0.8bn higher than announced on 21 December 2012, and represent estimated earnings and other improvements in statutory surplus over the period from 30 June 2012 to 30 September 2013. Cash proceeds to Aviva are US$0.8 billion higher than announced on 21 December 2012, at US$2.3bn (£1.5bn), following repayment of an external loan of Aviva USA.

Mark Wilson, Group Chief Executive Officer, said:

"This is a solid outcome with transaction proceeds of US$2.6 billion. The sale of the US business is another milestone for Aviva: it simplifies the business, strengthens the capital position and is a step towards our goal of creating a business focused on cash flow and growth."

Merrill Lynch note today:
"Aviva has announced that it has completed the disposal of its US life business to Athene Holdings Ltd. Whilst not surprising given regulatory hurdles were known to have been cleared, the completion of the deal is a major step forward in Aviva’s restructuring and de-risking plans, in our view.
More importantly for the share price in the near term, the exit price is meaningfully higher than expected. The transaction proceeds are £1.7bn ($2.6bn), which i £0.5bn higher than announced in December last year. This is a reflection of improvements in the underlying business over the last nine months. After repayment of an external loan, cash proceeds to Aviva are expected to be £1.5bn. This £1.5bn will be used to cancel an internal loan between the US and the group (this was known), leaving £950m to be used for ‘general corporate purposes’.
Aviva has reported figures on a pro-forma basis since the announcement of the US disposal late last year. Therefore the only change to recently reported numbers is the uplift against the expected proceeds from the deal. The £0.5bn uplift is not subject to tax. But it is worth noting that the reported H1 book value included a £0.15bn uplift in the expected disposal price from market movements (we suspect many investors missed this). Therefore, we estimate there is a further £0.35bn positive adjustment to book value. This equates to 12p per share, which will probably drop to around 10p after transaction costs etc. This is 3.5% uplift to book value or 2.5% uplift against Aviva’s market cap. We would expect the shares to rise by this order of magnitude today.
Aviva remains an early stage restructuring story. We expect the shares to move higher in the coming 12 months mainly through a reduction in the cost of equity as the restructuring takes hold. During the period of de-leveraging, we expect Aviva’s ROE to be supported by significant cost savings. We estimate the shares are trading on 8.8x & 8.2x 2014E & 2015E IFRS EPS respectively; 1.35x IFRS book value; 3.8% dividend yield and 10.8% FCF yield. We reiterate our Buy rating and 475p PO."

Looks promising Harry.

3 October 2013

Aviva plc (the "Issuer") €650,000,000 Fixed/Floating Rate Subordinated Notes due 2023 (ISIN: XS0177448015) (the "Notes") Cancellation of Listing

The Issuer wishes to announce that it has, on 2 October 2013, in accordance with the Terms and Conditions of the Notes, redeemed the Notes in full and that the listing of the Notes on the Official List of the United Kingdom Listing Authority has been cancelled with effect from (and including) 3 October 2013.

The last six months on that chart look exceedingly good and we now have the promise of more to come. I had been looking to sell to reinvest in something with a higher yield, but I reckon I'll hold on for a while yet. That Merrill Lynch target of 475p would be rather nice. Worth holding for another 12 months to see just how close we get.

Societe Generale Buy 411.10 414.80 400.00 560.00 Retains

New 2+ year high this morning @427.10p

560 looks even more interesting than 475, Skinny. Looks like I could be here for some time yet.

Let's hope lord Gnome!

AVIVA APPOINTS PATRICIA CROSS AS NON-EXECUTIVE DIRECTOR

Aviva plc ("Aviva") has appointed Patricia Cross as an independent non-executive director of the Board with effect from 1 December 2013. She will also join the Board Audit, Remuneration and Nomination Committees.

Patricia has over thirty years' experience as both an executive and non-executive director across a wide range of financial services and other regulated industries in the US, Europe and Australia. She has served as a non-executive director of ASX-50 Australian companies for seventeen years, and is currently a non-executive director of Macquarie Group Limited and Macquarie Bank Limited where she is chairman of the Risk Committee and a member of the Audit Committee. She is also a non-executive director at Qantas Airways Limited where she is chairman of the Remuneration Committee and is a member of the Audit and Nomination Committees.

Until recently, Patricia was a non-executive director of National Australia Bank Limited (owner of Clydesdale Bank plc in the UK), where she chaired the Remuneration Committee, was a nominated FCA Approved Person, served as a Director of the wealth management subsidiary JB Were Pty Ltd, and was a member of the Risk and Nomination Committees. She has previously been a non-executive director of Wesfarmers Limited, Suncorp-Metway Limited and AMP Limited, all listed companies in Australia, and also served as Chairman of Qantas Superannuation Limited (the Qantas pension fund) and Deputy Chairman of the monoline third party insurer TAC in Victoria. Prior to becoming a non-executive director, Patricia worked for sixteen years in senior executive positions at National Australia Bank Limited, Chase Manhattan Bank, Chase Investment Bank and Banque Nationale de Paris.

Interim Management Statement

Canaccord Genuity Buy 434.15 460.00 460.00 Reiterates

Societe Generale Buy 434.15 560.00 560.00 Retains

Barclays Capital Underweight 434.15 - - Reiterates

JP Morgan Cazenove Overweight 434.15 486.00 486.00 Reiterates

I like the sound of 560. Thanks Societe Generale. They must be long on Aviva!

Aviva to Sell Stake in Italian Insurer Eurovita

AVIVA TO SELL STAKE IN ITALIAN INSURER EUROVITA


Aviva plc ("Aviva") announces today that it has reached a conditional agreement to sell its entire 39% stake in Eurovita Assicurazioni S.p.A. ("Eurovita") to JC Flowers ("JCF")1 for a total consideration of €33m, payable in cash. Proceeds will be used for general corporate purposes.The sale is subject to approval by IVASS, the Italian insurance regulator.

If approved, the transaction would increase Aviva's economic capital surplus by £0.1bn and will have no impact on Aviva's IFRS net assets. The agreement represents further progress in Aviva's strategy to focus our Italian business on more profitable, capital efficient products.

Eurovita is an Italian life insurer which distributes guaranteed savings products through a network of local and regional Italian banks. Eurovita contributed £6m to Aviva's IFRS profit after minorities in the first half of 2013. Eurovita had ca. £3bn IFRS total assets at 30 June 2013.

Eurovita is majority owned by Aviva and Banco Popolare. Banco Popolare has agreed to sell its entire stake in Eurovita to JCF.